Press Releases

August 14, 2018
CASI Pharmaceuticals Announces Second Quarter And First Half 2018 Financial And Business Results
July 03, 2018
CASI Pharmaceuticals Added To Russell 2000®, 3000® And Microcap® Indexes
June 21, 2018
CASI Pharmaceuticals Enters Strategic Partnering And Contract Manufacturing Agreement With Yiling Wanzhou International Pharmaceuticals For Entecavir And Cilostazol
May 29, 2018
CASI Pharmaceuticals To Present At The BIO International Convention
May 15, 2018
CASI Pharmaceuticals Announces First Quarter 2018 Financial And Business Results
April 05, 2018
CASI Pharmaceuticals Provides Update On Evomela®
April 03, 2018
CASI Pharmaceuticals To Present At The H.C. Wainwright Global Life Sciences Conference
March 29, 2018
CASI Pharmaceuticals Announces Fourth Quarter And Full Year 2017 Financial Results
March 20, 2018
CASI Pharmaceuticals Announces $50 Million Private Placement To Prepare Company For Commercialization In China
February 09, 2018
CASI Pharmaceuticals to Present at the BIO CEO & Investor Conference
January 26, 2018
CASI Pharmaceuticals Acquires ANDA Portfolio From Sandoz Inc. (Sandoz)
December 01, 2017
CASI Pharmaceuticals Announces Poster Presentation At The 2017 San Antonio Breast Cancer SymposiumTM (SABCS) On ENMD-2076 In Patients With Triple-Negative Breast Cancer (TNBC)
November 14, 2017
CASI Pharmaceuticals Reports Third Quarter 2017 Financial Results
October 13, 2017
CASI PHARMACEUTICALS ANNOUNCES $23.8 MILLION REGISTERED DIRECT OFFERING LED BY EXISTING SHAREHOLDERS
September 07, 2017
CASI Provides Pipeline Development Update
September 06, 2017
CASI Pharmaceuticals To Present At The Annual Rodman & Renshaw Global Investment Conference
August 14, 2017
CASI Pharmaceuticals Reports Second Quarter 2017 Financial Results
May 30, 2017
CASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Clear Cell Ovarian Carcinoma (CCOC)
May 18, 2017
CASI Pharmaceuticals Announces Abstract On ENMD-2076 In Clear Cell Ovarian Cancer
May 15, 2017
CASI Pharmaceuticals Reports First Quarter 2017 Financial Results

Page 3 of 13 pages < 1 2 3 4 5 > Last ›

INVESTOR CONTACT:

Jennifer Porcelli
Solebury Trout
740 Broadway
New York, NY 10003

Ph: 646.378.2962
Email: jporcelli@troutgroup.com

About Us

CASI is a U.S. NASDAQ-listed biopharmaceutical company with a platform to develop and accelerate the launch of pharmaceutical products and innovative therapeutics in China, the U.S., and throughout the world. We have offices in Rockville, Maryland, and a wholly owned subsidiary in Beijing, China, through which substantially all of our operations are conducted.

Downloads

Corporate Presentation

EVOMELA^® (melphalan) for Injection, ZEVALIN^® (ibritumomab tiuxetan), and MARQIBO^® (vincristine sulfate LIPOSOME injection) are proprietary to Acrotech Biopharma LLC and its affiliates.

CASI Pharmaceuticals

© 2020 CASI Pharmaceuticals Inc.
All Rights Reserved.